Specialty market
China IVF and Reproductive Medicine Market Outlook 2026
China's assisted reproductive technology market reached USD 6.2 billion in 2025 with a 16.5% CAGR through 2030, propelled by declining fertility, three-child policy support and growing inbound from Hong Kong, Singapore, Indonesia and Russia.
Market size (2025)
USD 6.20 billion
CAGR
16.5%
Forecast (2030)
USD 13.3 billion
Geography
Mainland China NHC-licensed assisted reproductive technology services
International-patient cost band
$5,500–$9,500 USD
Market size, 2021–2030
Mainland China NHC-licensed assisted reproductive technology services.
| Year | Market size (USD) | Status |
|---|---|---|
| 2021 | USD 2.95 billion | Historical |
| 2022 | USD 3.58 billion | Historical |
| 2023 | USD 4.36 billion | Historical |
| 2024 | USD 5.21 billion | Historical |
| 2025 | USD 6.20 billion | Latest actual |
| 2026 | USD 7.22 billion | Forecast |
| 2030 | USD 13.3 billion | Forecast |
Demand drivers
- Total fertility rate fell to 1.02 in 2024; policy support shifted from anti-natalist to pro-natalist.
- Three-child policy (2021) and subsequent provincial IVF reimbursement: Beijing, Inner Mongolia, Guangxi, others now reimburse 16 ART procedures.
- Average maternal age at first birth rose to 28.3 — driving demand for IVF, PGT and donor-egg cycles.
- Inbound demand: HK and Macau cross-border, Singapore expat (China-based), Russian patients post-2022 sanctions.
Supply-side landscape
- ~600 NHC-licensed ART centres nationwide; ~250 with full PGT-A/M/SR capability.
- Top centres: PKU Third Hospital, Shenzhen Maternity & Child, Beijing Obstetrics & Gynecology, PUMCH, Sun Yat-sen Memorial, Renji Shanghai.
- Cost: USD 5,500–9,500 per cycle all-in at Class A international departments; vs US USD 18,000–30,000.
Risks & headwinds
- Surrogacy prohibited in mainland China — international patients seeking surrogacy generally route to USA or Georgia.
- Egg donation restricted to leftover-egg-sharing model — no commercial donor egg market.
- Same-sex and single-woman IVF restricted in most provinces (legal in HK and Macau for some pathways).
Notable providers
Class A
PKU Third Hospital ART
China's flagship reproductive medicine centre; world's first birth from frozen embryo in China.
Class AShenzhen Maternity & Child
Highest-volume IVF programme in southern China.
Class ABeijing Obstetrics & Gynecology
Capital Medical-affiliated; strong PGT programme.
Class ASun Yat-sen Memorial Hospital
Major Guangzhou IVF centre serving Greater Bay Area.
Frequently asked
- How big is the China IVF market in 2026?
- USD 6.2 billion in 2025, forecast to USD 13.35 billion by 2030 (16.5% CAGR) — the fastest-growing major specialty market in Chinese healthcare. Provincial IVF reimbursement expansion is the primary growth driver.
- Can international patients access IVF in China?
- Yes — most NHC-licensed centres accept international patients; married heterosexual couples qualify under current regulation. Same-sex and single-woman IVF is restricted in mainland China but accessible in Hong Kong and Macau.
- How much does a full IVF + ICSI cycle cost in China?
- USD 5,500–9,500 all-in at a Class A international department, including stimulation medications, monitoring, retrieval, ICSI, fresh transfer, and pregnancy follow-up to week 12. Frozen embryo transfers are USD 1,800–3,200.
Sources
- National Health Commission ART licensed-centre directory 2025
- Chinese Society of Reproductive Medicine annual volume report 2024
- China Insights Consultancy ART Market Outlook 2025
- Partner-network 2026 international-patient IVF quote data
Last reviewed: 2026-05-12.
Going beyond the report
For a written quote from two Class A international departments — covering procedure, hospital match, recovery and visa — start the quote wizard.